2023 Q1 Form 10-K Financial Statement

#000147793223002099 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $3.517M $1.377M $3.826M
YoY Change 517.1% 49.06%
% of Gross Profit
Research & Development $207.3K $94.44K $1.274M
YoY Change -29.25% 2960.65%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $3.725M $1.472M $5.099M
YoY Change 334.0% 95.51%
Operating Profit -$3.725M -$5.099M
YoY Change 334.0%
Interest Expense -$540.00 $1.480K $3.380K
YoY Change 2716.67%
% of Operating Profit
Other Income/Expense, Net $109.7K $166.2K $153.9K
YoY Change 16403.16%
Pretax Income -$3.615M -$1.304M -$4.945M
YoY Change 320.36% 89.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.615M -$1.304M -$4.945M
YoY Change 321.54% 89.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.18
Diluted Earnings Per Share -$0.12 -$0.06 -$0.18
COMMON SHARES
Basic Shares Outstanding 37.39M shares 34.36M shares 26.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.082M $2.389M $2.389M
YoY Change -19.11%
Cash & Equivalents $5.082M $2.389M
Short-Term Investments
Other Short-Term Assets $688.3K $913.0K $913.0K
YoY Change 241.24%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $5.771M $3.302M $3.302M
YoY Change 2.51% 2.51%
LONG-TERM ASSETS
Property, Plant & Equipment $8.006M $8.201M $9.054M
YoY Change 174.43% 130.9%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $133.6K $139.6K $139.6K
YoY Change
Total Long-Term Assets $8.836M $9.194M $9.194M
YoY Change 134.46% 134.46%
TOTAL ASSETS
Total Short-Term Assets $5.771M $3.302M $3.302M
Total Long-Term Assets $8.836M $9.194M $9.194M
Total Assets $14.61M $12.50M $12.50M
YoY Change 74.95% 74.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.287M $1.355M $1.355M
YoY Change 2170.32% 2170.27%
Accrued Expenses $408.6K $361.2K $407.2K
YoY Change 749.99% 405.34%
Deferred Revenue
YoY Change
Short-Term Debt $33.85K $33.85K $33.85K
YoY Change -27.83%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.996M $1.936M $1.936M
YoY Change 538.32% 538.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $698.0K $742.4K $742.4K
YoY Change -11.78%
Total Long-Term Liabilities $698.0K $742.4K $742.4K
YoY Change -11.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.996M $1.936M $1.936M
Total Long-Term Liabilities $698.0K $742.4K $742.4K
Total Liabilities $2.694M $2.679M $2.679M
YoY Change 133.96% 133.96%
SHAREHOLDERS EQUITY
Retained Earnings -$11.17M -$7.553M
YoY Change 189.62%
Common Stock $373.9K $359.1K
YoY Change 73.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.91M $9.817M $9.817M
YoY Change
Total Liabilities & Shareholders Equity $14.61M $12.50M $12.50M
YoY Change 74.95% 74.95%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$3.615M -$1.304M -$4.945M
YoY Change 321.54% 89.62%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$1.445M -$862.0K -$2.940M
YoY Change 401.82% 408.9%
INVESTING ACTIVITIES
Capital Expenditures $362.1K $902.5K $4.473M
YoY Change -59.72% 49.69%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$362.1K -$902.5K -$4.473M
YoY Change -59.72% 49.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.120M
YoY Change 21.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $4.494M 3.790M $6.641M
YoY Change 101.24% 2.16%
NET CHANGE
Cash From Operating Activities -$1.445M -862.0K -$2.940M
Cash From Investing Activities -$362.1K -902.5K -$4.473M
Cash From Financing Activities $4.494M 3.790M $6.641M
Net Change In Cash $2.687M 2.026M -$772.0K
YoY Change 156.82% -126.3%
FREE CASH FLOW
Cash From Operating Activities -$1.445M -$862.0K -$2.940M
Capital Expenditures $362.1K $902.5K $4.473M
Free Cash Flow -$1.807M -$1.765M -$7.413M
YoY Change 52.25% 107.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001921865
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20652500 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35907127 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
342200 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
380747 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
700000 usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39069
CY2022 dei Entity Registrant Name
EntityRegistrantName
ASP Isotopes Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2618235
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
433 Plaza Real
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 275
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
CY2022 dei City Area Code
CityAreaCode
561
CY2022 dei Local Phone Number
LocalPhoneNumber
709-3034
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.01 per share
CY2022 dei Trading Symbol
TradingSymbol
ASPI
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
8100000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37385684 shares
CY2022 dei Auditor Firm
AuditorFirmId
274
CY2022 dei Auditor Name
AuditorName
EisnerAmper LLP
CY2022 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2022Q4 us-gaap Cash
Cash
2389140 usd
CY2021Q4 us-gaap Cash
Cash
2953721 usd
CY2022Q4 f10q0922 Fair Value Of Shares Issuable
FairValueOfSharesIssuable
140455 usd
CY2021Q4 f10q0922 Fair Value Of Shares Issuable
FairValueOfSharesIssuable
116200 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
18723 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20652500 shares
CY2022 f10q0922 Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
150527 usd
f10q0922 Change In Fair Value Of Share Liability
ChangeInFairValueOfShareLiability
0 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3382 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
115 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
153909 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
115 usd
CY2022 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-4945139 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-2607927 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26793748 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16246432 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4945139 usd
us-gaap Net Income Loss
NetIncomeLoss
-2607927 usd
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
236307 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18723 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4708832 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2589204 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
0 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
500000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6337800 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1735841 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13227 usd
us-gaap Net Income Loss
NetIncomeLoss
-2607927 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5997664 usd
CY2022 f10q0922 Stock Issued During Period Values
StockIssuedDuringPeriodValues
2738812 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1209496 usd
CY2022 f10q0922 Proceeds From Issuance Of Common Stock Issue
ProceedsFromIssuanceOfCommonStockIssue
3790504 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2022 f10q0922 Issuance Of Restricted Shares Amount
IssuanceOfRestrictedSharesAmount
0 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1999313 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
236307 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4945139 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9817461 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4945139 usd
us-gaap Net Income Loss
NetIncomeLoss
-2607927 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1999313 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13227 usd
CY2022 f10q0922 Issuance Of Common Stock To Founders
IssuanceOfCommonStockToFounders
0 usd
f10q0922 Issuance Of Common Stock To Founders
IssuanceOfCommonStockToFounders
500000 usd
CY2022 f10q0922 Issuance Of Warrant To Purchase Common Stock
IssuanceOfWarrantToPurchaseCommonStock
0 usd
f10q0922 Issuance Of Warrant To Purchase Common Stock
IssuanceOfWarrantToPurchaseCommonStock
1735841 usd
CY2022 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
50000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2022 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-150527 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
72570 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
19376 usd
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-671924 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-267562 usd
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-146435 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
570600 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
59679 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
319048 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
42500 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-37399 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-72826 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2939893 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-577692 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4473164 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2988210 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4473164 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2988210 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8119959 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6680000 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1465461 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
226000 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
46900 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
13046 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6641052 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6500900 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-772005 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2934998 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
207424 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18723 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953721 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2389140 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953721 usd
CY2022 us-gaap Stock Issued1
StockIssued1
124782 usd
CY2022 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
6050000 usd
us-gaap Stock Issued1
StockIssued1
116200 usd
CY2022 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
745628 usd
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
0 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
952521 usd
CY2022Q4 us-gaap Share Price
SharePrice
4.00
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3800000 usd
CY2022 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
4945139 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
2607927 usd
CY2022Q4 us-gaap Cash
Cash
2389140 usd
CY2022 f10q0922 Amount Received
AmountReceived
gross proceeds of $5.0 million received in March 2023 through the issuance of 3,164,557 shares of the Company's common stock
CY2022 us-gaap Common Stock Convertible Conversion Price Decrease
CommonStockConvertibleConversionPriceDecrease
1.58
CY2022 f10q0922 Warrants Purchase Aggregate
WarrantsPurchaseAggregate
3164557 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the years ended December 31, 2022 and 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Our foreign subsidiaries held cash of approximately $38,000 and $20,000 as of December 31, 2022 and 2021, respectively, which is included in cash on the consolidated balance sheets.  Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S.  If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.</p>
CY2022Q4 f10q0922 Federal Deposit Insurance
FederalDepositInsurance
250000 usd
CY2022Q4 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
38000 usd
CY2021Q4 us-gaap Common Stock Held By Subsidiary
CommonStockHeldBySubsidiary
20000 usd
CY2022Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
140455 usd
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2021Q4 f10q0922 Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
116200 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
116200 usd
CY2022 f10q0922 Addition On Issuance Of Common Stock
AdditionOnIssuanceOfCommonStock
174782 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-150527 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
140455 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
8200595 usd
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2988210 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
10000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
33854 usd
CY2022 us-gaap Loss On Contracts
LossOnContracts
6800000 usd
CY2022Q4 us-gaap Other Commitment
OtherCommitment
7233000 usd
CY2021Q4 us-gaap Other Commitment
OtherCommitment
1800000 usd
CY2021Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.075 pure
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
952521 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
952521 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
853889 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45903 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
742443 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
125667 usd
CY2021Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
19376 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
93211 usd
CY2021Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
26582 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2021Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
952521 usd
CY2022 f10q0922 Remaining Lease Term Years
RemainingLeaseTermYears
P8Y
CY2021Q4 f10q0922 Remaining Lease Term Years
RemainingLeaseTermYears
P9Y
CY2022 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2021Q4 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.075 pure
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
103543 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
111308 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
119656 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
128631 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
138278 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
480229 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1081645 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
293299 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
788346 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45903 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
742443 usd
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
100000 usd
CY2022Q1 f10q0922 Royalty Percentage On Sale Of Products
RoyaltyPercentageOnSaleOfProducts
0.10 pure
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000000 zar
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.765 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0021 pure
CY2022 f10q0922 Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P2Y
CY2022 f10q0922 Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6000000 shares
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
400000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
400000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.25
f10q0922 Weighted Average Remaining Contractual Term
WeightedAverageRemainingContractualTerm
P9Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
700000 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2751000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
250000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2901000 shares
CY2022 f10q0922 Weighted Average Remaining Contractual Term
WeightedAverageRemainingContractualTerm
P1Y10M28D
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P9Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
199500 usd
CY2022 f10q0922 Number Of Options Exercisable
NumberOfOptionsExercisable
418749 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
1.76
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2022 f10q0922 Aggregate Intrinsic Value Exercisable
AggregateIntrinsicValueExercisable
77583 usd
CY2022 f10q0922 Number Of Options Vested Or Expected To Vests
NumberOfOptionsVestedOrExpectedToVests
2901000 shares
CY2022 f10q0922 Weighted Average Exercise Price Per Share Vested Or Expected To Vest
WeightedAverageExercisePricePerShareVestedOrExpectedToVest
1.91
CY2022 f10q0922 Weighted Average Remaining Contractual Termin Years Vested Or Expected To Vest
WeightedAverageRemainingContractualTerminYearsVestedOrExpectedToVest
P9Y4M24D
CY2022 f10q0922 Aggregate Intrinsic Value Vested Or Expected To Vest
AggregateIntrinsicValueVestedOrExpectedToVest
199500 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2100000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.25
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2100000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.25
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
5250000 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.24
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
350000 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.75
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1999313 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
513227 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-4945139 usd
us-gaap Profit Loss
ProfitLoss
-2607927 usd
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
26793745 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
16246432 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
496751 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2901000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
400000 shares
CY2022Q4 f10q0922 Restricted Stock
RestrictedStock
7000000 shares
CY2021Q4 f10q0922 Restricted Stock
RestrictedStock
0 shares
CY2022 f10q0922 Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
0 shares
f10q0922 Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
7230822 shares
CY2022 f10q0922 Shares Of Common Stock Equivalents
SharesOfCommonStockEquivalents
9901000 shares
f10q0922 Shares Of Common Stock Equivalents
SharesOfCommonStockEquivalents
7630822 shares
CY2022 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-4945139 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-2607927 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2022 f10q0922 Earnings In Jurisdictions Taxed At Rates Different From The Statutory Us Federal Tax Rate
EarningsInJurisdictionsTaxedAtRatesDifferentFromTheStatutoryUSFederalTaxRate
-0.0589 pure
f10q0922 Earnings In Jurisdictions Taxed At Rates Different From The Statutory Us Federal Tax Rate
EarningsInJurisdictionsTaxedAtRatesDifferentFromTheStatutoryUSFederalTaxRate
0.0411 pure
CY2022 f10q0922 Permanent Differences Income Tax Rate
PermanentDifferencesIncomeTaxRate
0.0064 pure
f10q0922 Permanent Differences Income Tax Rate
PermanentDifferencesIncomeTaxRate
-0.2295 pure
CY2022 f10q0922 Other Statutory Rate
OtherStatutoryRate
0.0298 pure
f10q0922 Other Statutory Rate
OtherStatutoryRate
0 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1873 pure
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0216 pure
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
140241 usd
CY2022Q4 f10q0922 Capitalized Rd Costs
CapitalizedRDCosts
50289 usd
CY2021Q4 f10q0922 Capitalized Rd Costs
CapitalizedRDCosts
0 usd
CY2022Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
418019 usd
CY2021Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
0 usd
CY2022Q4 f10q0922 Right Of Use Lease Liability
RightOfUseLeaseLiability
243113 usd
CY2021Q4 f10q0922 Right Of Use Lease Liability
RightOfUseLeaseLiability
264249 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1208172 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
404490 usd
CY2022Q4 f10q0922 Deferred Tax Assets
DeferredTaxAssets
977622 usd
CY2021Q4 f10q0922 Deferred Tax Assets
DeferredTaxAssets
51518 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
977622 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51518 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022 us-gaap Real Estate Owned Valuation Allowance Valuation Increase
RealEstateOwnedValuationAllowanceValuationIncrease
926104 usd
CY2022 us-gaap Common Stock Convertible Conversion Price Decrease
CommonStockConvertibleConversionPriceDecrease
1.58

Files In Submission

Name View Source Status
0001477932-23-002099-index-headers.html Edgar Link pending
0001477932-23-002099-index.html Edgar Link pending
0001477932-23-002099.txt Edgar Link pending
0001477932-23-002099-xbrl.zip Edgar Link pending
aspi_10k.htm Edgar Link pending
aspi_10kimg2.jpg Edgar Link pending
aspi_10kimg3.jpg Edgar Link pending
aspi_10kimg4.jpg Edgar Link pending
aspi_ex1018.htm Edgar Link pending
aspi_ex1018img1.jpg Edgar Link pending
aspi_ex1018img2.jpg Edgar Link pending
aspi_ex1019.htm Edgar Link pending
aspi_ex1019img1.jpg Edgar Link pending
aspi_ex1019img2.jpg Edgar Link pending
aspi_ex1020.htm Edgar Link pending
aspi_ex1020img2.jpg Edgar Link pending
aspi_ex1021.htm Edgar Link pending
aspi_ex1021img2.jpg Edgar Link pending
aspi_ex211.htm Edgar Link pending
aspi_ex231.htm Edgar Link pending
aspi_ex311.htm Edgar Link pending
aspi_ex312.htm Edgar Link pending
aspi_ex321.htm Edgar Link pending
aspi_ex322.htm Edgar Link pending
f10q0922-20221231.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
f10q0922-20221231_cal.xml Edgar Link unprocessable
f10q0922-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0922-20221231_lab.xml Edgar Link unprocessable
aspi_10k_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
f10q0922-20221231_pre.xml Edgar Link unprocessable